Tristel's Record Year Is a Spending Mandate, Not a Victory Lap

A new CEO, a £16m cash pile and a suddenly urgent U.S. push turn a familiar small-cap compounder into a capital-allocation story.

TSTL.L · Earnings Call · 2026-10-19

A record year, and a new hand on the wheel

Tristel's FY26 results look like the same small-cap compounder investors have owned for years: revenue up 10% to a record £51.1m, adjusted PBT up 15% to £11.7m, a 31% adjusted EBITDA margin, £16m of cash and no debt. Anna Wasyl frames it plainly: “Our revenues reached a record GBP 51.1 million and grew across the world in the U.K., our home market, by 5% and overseas by 13%.” — Anna Wasyl, Chief Financial Officer (CFO) · 2026-10-19 Chris Lee, three months into the CEO seat, opens with “I'm delighted to present what's going to be an outstanding set of numbers for the business.” — Christopher Lee, Chief Executive Officer (CEO) · 2026-10-19 Fair enough. But the interesting bit is not the print. It is that a new CEO is using a record year to argue for more investment, not more distribution. That is a change in tone. The prior March call, still under Matthew Sassone, was defensive on the U.S. The first investor question was blunt: “What specifically is your strategy and operational actions for growing sales in the U.S. as traction appears to be slow?” — Operator · 2026-03-02 Julija Shabanova conceded “Initial pace may have been slower than expected” — Julija Shabanova, Executive Director · 2026-03-02 before pointing to guidelines and key-opinion-leader work. Six months later, Lee is not apologising for the U.S.; he is re-underwriting it.

The U.S. is no longer a promise—it is an investment line

The operating numbers have moved. Americas revenue reached £0.8m, up 202%, with U.S. ultrasound procedures rising from 300,000 to 736,000 and OPH revenue at $260,000. There are now 73 OPH accounts and 304 open opportunities, 207 in trial or evaluation. Lee calls the U.S. “the biggest medical device market in the world with some of the most attractive prices in the world as well” — Christopher Lee, Chief Executive Officer (CEO) · 2026-10-19 and says Tristel can do an awful lot more. The plan is more feet on the ground: sales specialists, clinical specialists and marketing support, alongside Parker Laboratories on ultrasound and Tristel's direct team on ophthalmology. The phrase clinical specialists is not new—it topped the prior quarter's keyword extract—but the current call converts it from aspiration into a budget line. That matters because the U.S. model is not a simple distributor lever. Parker manufactures in the U.S., which quietly neutralises tariffs; a dedicated tariff question that appeared in March is absent from today's Q&A. The trade-off is that Tristel does not control the ultrasound sales motion. Lee is now trying to influence it with clinical support rather than waiting for Parker's pace to improve. There is also a fresh quantification of the existing base. Lee says bringing all direct markets up to the median distribution of products per customer would be worth roughly £40m, with up to £60m from internal benchmarks across market-maturity levels. That makes existing markets the fastest lever, before new geographies or M&A. It is a penetration story dressed as a growth story—and for a company with 82% gross margin, penetration is highly incremental.

Unifoam, 3T and the clinical moat

The new-product pipeline is where the call gets more company-specific. Unifoam targets hospital drains, a niche that is finally being taken seriously because sinks and drains act as reservoirs for drug-resistant bacteria. Wasyl says the soft launch at the IPS conference in Leeds produced “14 NHS trusts registering for trials just on this conference itself” — Anna Wasyl, Chief Financial Officer (CFO) · 2026-10-19, with a first-phase launch in core European markets and the U.K. planned for January. The chemistry is the differentiator: chlorine dioxide penetrates biofilm in a way that chlorine, peracetic acid and hot water do not. 3T Pro is the other new revenue stream. It went live at the end of June in the U.K., U.S., Australia and New Zealand—markets covering 80% of current 3T users—and now has more than 270 customers, with 48,000 staff certificates issued. The paid tier is meant to make compliance sticky: if hospitals rely on 3T to train, certify and audit decontamination, switching away from Tristel's chemistry becomes harder. That is a software moat wrapped around a consumable. The competitive backdrop is familiar. Nanosonics' trophon is the established automated competitor; Lee argues it operates in capital systems, not manual high-level disinfection. UV-C remains noisy but flawed by shadows and real-world validation. In March, Sassone said Tristel would “continue to see Nanosonics as a competitor” — Matthew Sassone, Management Team Member · 2026-03-02; today Lee says Tristel is the only manual high-level disinfection player with chlorine dioxide, protected by patents, formulation know-how and device manufacturers compatibility. The moat is real, but it is being defended with education: Tristel Academy, key opinion leaders and clinical evidence. That is a slower, more expensive moat than a patent alone.

Cash, competition and the buyback temptation

The awkward question is what to do with the cash. Tristel ended the year debt-free with £16m and a progressive dividend rising 5% to 14.91p. Investors asked about a special dividend and buyback. Wasyl's answer was unusually direct—and unusually competitive:

Some people may say that arranging for a share buyback actually sends the message that the management think the shares are undervalued, which we can definitely confirm that is the case. But on the other hand, it may also mean that we believe that we don't have a more attractive way of investing it ourselves... We have a great example actually of our competitor, Nanosonics... They have spent significant amounts of cash last year and this year on share buyback... and their share price is currently at 40% below last year.
Anna Wasyl, Chief Financial Officer (CFO) · 2026-10-19

That is a striking way to argue against buybacks: look at the competitor that did it. It also reveals the new CEO's priority. Lee wants optionality for U.S. acceleration, Unifoam capacity, clinical infrastructure and M&A. He explicitly mentions adjacent technologies and using deals to enter tricky markets like Japan, China or Brazil: “we would like to look at technologies that are either adjacent or in our space” — Christopher Lee, Chief Executive Officer (CEO) · 2026-10-19. That is a broader capital-allocation menu than Tristel has historically presented. The bear case writes itself. A £182m market-cap medtech with a new CEO, a concentrated U.S. partner, competition from Nanosonics and a cash pile that income investors would rather see returned. The share price has no tape in our context, so the report has to stand on operating evidence. On that evidence, FY26 is strong; the question is whether the new spending is disciplined or dilutive. The employee share scheme already caused dilution, and Wasyl says no new plan is in place, so that headwind should fade. Tristel is not a broken compounder. It is a compounder whose new CEO has decided the next leg requires investment before returns. The record year gives him the credibility to ask. The risk is that the market wanted a victory lap, not a spending mandate.